Death by oxymoron? the enigma of heart failure with preserved ejection fraction

Current Opinion in Supportive and Palliative Care

Volumn 8, Issue 1, 2014, Pages 1-3

  Beattie, James M ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLASSIFICATION; DIFFERENTIAL DIAGNOSIS; EDITORIAL; HEART FAILURE; HEART STROKE VOLUME; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY;

DIAGNOSIS, DIFFERENTIAL; HEART FAILURE; HUMANS; STROKE VOLUME;

EID: 84898004535     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0000000000000035     Document Type: Editorial

References (25)

1. McMurray JJ, Adamopoulos S, Anker SD, et al., ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14:803-869.
2. De Keulenaer GW, Brutsaert DL. Systolic and diastolic heart failure: different phenotypes of the same disease? Eur J Heart Fail 2007; 9:136-214.
3. Cioffi G, Senni M, Tarantini L, et al. Analysis of circumferential and longitudinal left ventricular systolic function in patients with nonischemic chronic heart failure and preserved ejection fraction (fromthe CARRY-IN-HFpEF study). Am J Cardiol 2012; 109:383-389.
4. Dunlay SM, Roger VL, Weston SA, et al. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail 2012; 5:720-726.
5. Paulus WJ, Tschö pe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28:2539-2550.
6. Penicka M, Vanderheyden M, Bartunek J. Diagnosis of heart failure with preserved ejection fraction: role of clinical Doppler echocardiography. Heart 2014; 100:68-76.
7. Zile MR, Gottdiener JS, Hetzel SJ, et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and preserved ejection fraction. Circulation 2011; 124:2491-2501.
8. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis and treatment. Eur Heart J 2011; 32:670-679.
9. Bhuiyan T, Maurer MS. Heart failure with preserved ejection fraction: persistent diagnosis, therapeutic enigma. Curr Cardiovasc Risk Rep 2011; 5:440-449.
10. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362:777-781.
11. Cleland JGF, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27:2338-2345.
12. Massie BM, Carson PE, McMurray JJV, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359:2456-2467.
13. Desai AS, Lewis EF, Li R, Solomon SD, et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction (TOPCAT). Am Heart J 2011; 162:966-972.
14. Van Veldhuisen DJ, McMurray JJV. Pharmacological treatment of heart failure with preserved ejection fraction: a glimpse of light at the end of the tunnel? Eur J Heart Fail 2013; 15:5-8.
15. Stevenson LW, Pande R. Witness to progress. Circ Heart Fail 2011; 4:390-392.
16. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355:260-269.
17. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355:251-259.
18. Rickenbacher P, PfistererM, Burkard T, et al. Why and how do elderly patients with heart failure die? Insights from the TIME-CHF study. Eur J Heart Fail 2012; 14:1218-1229.
19. Somaratne JB, Berry C, McMurray JJV, et al. The prognostic significance of heart failure with preserved left ventricular ejection: a literature-based metaanalysis. Eur J Heart Fail 2009; 11:855-862.
20. Komajda M, Carson PE, Hetzel S, et al. Factors associated with outcome in heart failure with preserved ejection fraction. Findings from the I-Preserve study. Circ Heart Fail 2011; 4:27-35.
21. Chan MMY, Lam CSP. How do patients with heart failure with preserved ejection fraction die? Eur J Heart Fail 2013; 15:604-613.
22. Zile MR, Gaasch WH, Anand IS, et al. Mode of death from patients with heart failure and preserved ejection fraction: results from the Irbesartan in heart failure with preserved ejection fraction (I-Preserve) trial. Circulation 2010; 121:1393-1405.
23. Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003; 42:1226-1233.
24. Van Veldhuisen DJ, Linssen GC, Jaarsma T, et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 2013; 61:1498-1506.
25. Cubbon RM, Gale CP, Kearney LC, et al. Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction. A study across therapeutic eras. Circ Heart Fail 2011; 4:396-403.